This article is more than 5 years old. Information may no longer be current.
Implant may offer safe alternative to MMC in glaucoma filtration surgery
Click Here to Manage Email Alerts
WASHINGTON — The Ologen collagen matrix implant may offer a safer alternative to mitomycin C in glaucoma filtration surgery, studies and surgical experience are showing, according to a speaker here.
At the American Glaucoma Society meeting, Steven R. Sarkisian, MD, discussed the results of several recent studies that show the comparative safety and efficacy of the Ologen implant (Aeon Astron) in trabeculectomy procedures against MMC.
“Ologen offers an opportunity for wound modulation while avoiding the most dreaded late complications we see with MMC,” he said.
Steven R. Sarkisian
While a large, multicenter, prospective study comparing Ologen with MMC in trabeculectomy is currently under way, studies to date have shown comparable efficacy, he said. He cited a retrospective study of Ologen vs. MMC as wound modulators in trabeculectomy with an Ex-Press glaucoma shunt (Alcon). At 1 year, there was no statistically significant difference in qualified or unqualified success in IOP reduction between Ologen and MMC. The study was published in the Journal of Glaucoma.
Sarkisian stressed that for surgeons to be successful with the Ologen implant, they would need to modify their surgical technique from MMC in trabeculectomy. He recommended two sutures instead of three to seven, as would be done with MMC. He also recommended against tying those sutures too tightly and not waiting 3 weeks to remove the sutures.
Reference:
Johnson MS, et al. J Glaucoma. 2013;doi:10.1097/IJG.0000000000000018.
Disclosure: Sarkisian is a paid consultant to Aeon Astron.